ES2193406T3 - Composiciones y metodos para mejorar la funcion intestinal. - Google Patents

Composiciones y metodos para mejorar la funcion intestinal.

Info

Publication number
ES2193406T3
ES2193406T3 ES97946986T ES97946986T ES2193406T3 ES 2193406 T3 ES2193406 T3 ES 2193406T3 ES 97946986 T ES97946986 T ES 97946986T ES 97946986 T ES97946986 T ES 97946986T ES 2193406 T3 ES2193406 T3 ES 2193406T3
Authority
ES
Spain
Prior art keywords
compositions
methods
lpg
intestinal function
improve intestinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97946986T
Other languages
English (en)
Inventor
Daniel J Drucker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
1149336 Ontario Inc
Original Assignee
1149336 Ontario Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 1149336 Ontario Inc filed Critical 1149336 Ontario Inc
Application granted granted Critical
Publication of ES2193406T3 publication Critical patent/ES2193406T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

EL GLP - 2 ESTIMULA EL CRECIMIENTO DEL TEJIDO TANTO DEL INTESTINO DELGADO COMO DEL INTESTINO GRUESO, CUANDO SE ADMINISTRA JUNTO CON OTROS AGENTES. LA INVENCION PROPORCIONA COMPOSICIONES FARMACEUTICAS DE GLP - 2 CON AL MENOS OTRO AGENTE QUE AUMENTE LA ACTIVIDAD BIOLOGICA DEL GLP - 2, PROCEDIMIENTOS PARA FOMENTAR EL CRECIMIENTO DEL TEJIDO TANTO DEL INTESTINO DELGADO COMO DEL GRUESO, Y PARA MEJORAR LOS TRASTORNOS NUTRICIONALES O GASTROINTESTINALES, GRACIAS A UN AUMENTO DE LOS NIVELES SERICOS DE GLP - 2 Y AL MENOS OTRO AGENTE, DESCRIBIENDOSE TAMBIEN KITS PARA LLEVAR A LA PRACTICA LOS PROCEDIMIENTOS DE LA INVENCION.
ES97946986T 1996-12-10 1997-12-10 Composiciones y metodos para mejorar la funcion intestinal. Expired - Lifetime ES2193406T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/763,177 US5952301A (en) 1996-12-10 1996-12-10 Compositions and methods for enhancing intestinal function

Publications (1)

Publication Number Publication Date
ES2193406T3 true ES2193406T3 (es) 2003-11-01

Family

ID=25067085

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97946986T Expired - Lifetime ES2193406T3 (es) 1996-12-10 1997-12-10 Composiciones y metodos para mejorar la funcion intestinal.

Country Status (10)

Country Link
US (1) US5952301A (es)
EP (1) EP0944396B1 (es)
AT (1) ATE233096T1 (es)
AU (1) AU5220098A (es)
CA (1) CA2274596C (es)
DE (1) DE69719360T2 (es)
DK (1) DK0944396T3 (es)
ES (1) ES2193406T3 (es)
PT (1) PT944396E (es)
WO (1) WO1998025644A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020025933A1 (en) * 1996-08-30 2002-02-28 Knudsen Liselotte Bjerre GLP-2 derivatives
CA2236519C (en) * 1997-05-02 2011-09-13 1149336 Ontario Inc. Methods of enhancing functioning of the large intestine
MXPA99010523A (es) * 1997-05-16 2004-09-01 Ontario Inc 1149336 Metodos para mejorar el funcionamiento del tractogastrointestinal superior.
US6803357B1 (en) * 1998-02-02 2004-10-12 New England Medical Center Hospitals, Inc. Method of regulating glucose metabolism, and reagents related thereto
WO1999058144A1 (en) * 1998-05-11 1999-11-18 1149336 Ontario Inc. Methods of enhancing functioning of the large intestine
US6979697B1 (en) 1998-08-21 2005-12-27 Point Therapeutics, Inc. Regulation of substrate activity
AU5480199A (en) * 1998-08-21 2000-03-14 Point Therapeutics, Inc. Regulation of substrate activity
GB9906714D0 (en) 1999-03-23 1999-05-19 Ferring Bv Compositions for improving fertility
GB9906715D0 (en) 1999-03-23 1999-05-19 Ferring Bv Compositions for promoting growth
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
AU781897B2 (en) * 1999-05-25 2005-06-23 Point Therapeutics, Inc. Anti-tumor comprising boroproline compounds
EP1806138A1 (en) * 1999-05-25 2007-07-11 Point Therapeutics, Inc. Anti-tumor agents comprising boroproline compounds
JP2003534237A (ja) * 1999-11-03 2003-11-18 ノボ ノルディスク アクティーゼルスカブ 食欲の抑制又は満腹の惹起のための成長ホルモン又は成長ホルモン分泌促進物質の使用
US6599882B1 (en) 1999-11-05 2003-07-29 Joseph A. Rogoff Secretin and secretin pharmaceuticals for treating lactose intolerance
GB9930882D0 (en) * 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
US20080249016A1 (en) * 2000-09-18 2008-10-09 Sanos Bioscience A/S Use of GLP-2 in a combination treatment for bone-related disorders
JP5161412B2 (ja) 2000-09-18 2013-03-13 サノス・バイオサイエンス・アクティーゼルスカブ Ｇｌｐ−１及びｇｌｐ−２ペプチドの使用方法
US7371721B2 (en) * 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
US20070135345A1 (en) * 2000-09-18 2007-06-14 Henriksen Dennis B Use of GLP-2 for the treatment or prevention, of bone-related disorders
AU2002233089B2 (en) * 2001-02-16 2005-12-22 Conjuchem Biotechnologies Inc. Long lasting glucagon-like peptide 2 (GLP-2) for the treatment of gastrointestinal diseases and disorders
AU2002357767C1 (en) * 2001-11-26 2009-03-19 Trustees Of Tufts College Peptidomimetic inhibitors of post-proline cleaving enzymes
WO2003045228A2 (en) * 2001-11-26 2003-06-05 Trustees Of Tufts College Methods for treating autoimmune disorders, and reagents related thereto
US20040038864A1 (en) * 2002-06-27 2004-02-26 Per Balschmidt Use of dimethyl sulfone as isotonicity agent
WO2004035624A2 (en) * 2002-10-14 2004-04-29 Novo Nordisk A/S Glucagon - like peptide - 2 variants
US20050026859A1 (en) * 2002-11-12 2005-02-03 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
US20080026077A1 (en) * 2002-11-12 2008-01-31 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
KR100918322B1 (ko) * 2003-11-12 2009-09-22 페노믹스 코포레이션 헤테로시클릭 보론산 화합물
US7317109B2 (en) * 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7576121B2 (en) * 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7767828B2 (en) * 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
JP2008506651A (ja) * 2004-07-14 2008-03-06 ノバルティス アクチエンゲゼルシャフト Ｄｐｐ−ｉｖ阻害剤と５−ｈｔ３および／または５−ｈｔ４受容体を調節する化合物の組合せ剤
KR101200227B1 (ko) 2005-05-04 2012-11-13 질랜드 파마 에이/에스 글루카곤 유사 펩티드-2(ｇｌｐ-2) 유사체
US7825139B2 (en) * 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
JP5819586B2 (ja) 2006-11-08 2015-11-24 ジーランド ファーマ アクティーゼルスカブ 選択的グルカゴン様ペプチド−２（ｇｌｐ−２）類似体
US20110295151A1 (en) * 2010-05-26 2011-12-01 Bakos Gregory J Enteroendocrine Manipulation for Metabolic Effect
AU2013255752B2 (en) 2012-05-03 2017-11-09 Zealand Pharma A/S Glucagon-like-peptide-2 (GLP-2) analogues
EP3019188B1 (en) 2013-07-08 2022-03-09 The University of Utah Research Foundation A peptide and the use thereof in the treatment of inflammatory disorders
CN106167789B (zh) * 2015-05-21 2020-08-04 中国科学院上海营养与健康研究所 低氧处理的间充质干细胞及其应用
CN106589110B (zh) * 2015-10-15 2020-01-17 上海迈迹生物医药科技有限公司 包含聚合物和glp-2衍生物的缀合物
AU2017371516C1 (en) 2016-12-09 2021-09-02 Zealand Pharma A/S Acylated GLP-1/GLP-2 dual agonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2120626C (en) * 1991-10-07 2009-10-06 Douglas Wilmore Method for enhancing gut absorption
NZ260309A (en) * 1992-06-08 1997-07-27 Pharmacia Ab Substituted For K Use of 1gf-2 for prevention or treatment of nutritional or gastrointestinal disorders and promoting neonatal growth
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
CA2251576C (en) * 1996-04-12 2012-08-21 1149336 Ontario Inc. Glucagon-like peptide-2 analogs

Also Published As

Publication number Publication date
DE69719360T2 (de) 2003-12-04
ATE233096T1 (de) 2003-03-15
CA2274596C (en) 2004-11-09
PT944396E (pt) 2003-07-31
DK0944396T3 (da) 2003-06-23
US5952301A (en) 1999-09-14
AU5220098A (en) 1998-07-03
DE69719360D1 (de) 2003-04-03
WO1998025644A1 (en) 1998-06-18
CA2274596A1 (en) 1998-06-18
EP0944396B1 (en) 2003-02-26
EP0944396A1 (en) 1999-09-29

Similar Documents

Publication Publication Date Title
ES2193406T3 (es) Composiciones y metodos para mejorar la funcion intestinal.
ES2179351T3 (es) Amidas acidas de piridil alqueno y piridil alquino como citoestaticos e inmunosupresores.
BR9910251A (pt) Estimulação hematopoiética
AR039133A2 (es) Canula
UY24805A1 (es) Peptidos y compuestos que se enlazan al receptor de la trombopoyetina
EA199901107A1 (ru) Системы и устройства для лечения переломов костей или больных костей с помощью расширяемых тел (варианты), стерильный набор инструментов для введения в кость (варианты)
DK124091A (da) Farmaceutisk genprodukt
ES2181725T3 (es) Inhibidores de hiv proteasa.
BR0103256A (pt) Utilização de substâncias bioquìmicas para uma composição para a prevenção e tratamento de condições de saúde causadas por constrição de células de músculo liso em órgãos do corpo humano
CR9879A (es) Moduladores de ccr5 (divisional de la solicitud n° 6392)
ES2183486T3 (es) Formulaciones de fsh y de variantes de fsh que comprenden alcohol bencilico como agente preservativo.
ES2040727T3 (es) Un proceso para preparar una formulacion en aerosol en solucion de un analogo.
BR0008787A (pt) Sistema à base de colágeno injetável para aplicação de células ou agentes terapêuticos
PT998287E (pt) Utilizacao de levobupivacaina
DE69625918T2 (de) Lang wirksames mittel zur rektalen verabreichung
PT952772E (pt) Processos de utilizacao de fagocitos mononuclears para promover a regeneracao axonal
ES2180729T3 (es) Tratamiento terapeutico combinado de las patologias hiperproliferantes.
DOP2002000369A (es) Composicion
ES2194312T3 (es) Compuestos de polimero-platino.
AU2003215878A8 (en) Stinging cells expressing an exogenous polynucleotide encoding a therapeutic, diagnostic or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derived therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue
ES2159357T3 (es) Derivados terpenoides (sarcodictinas) utiles como agentes antitumorales.
ES2172558T3 (es) Lubricante compatible con radiaciones para dispositivos medicos.
AR019327A1 (es) Combinacion de fentolamina y apomorfina para el tratamiento de la funcion y disfuncion sexual humana
BR9810452A (pt) Nova combinação de medicamentos contra asma
ES2138602T3 (es) Agente terapeutico para la amenaza de aborto.